Among them, the sGC activator MGV354 has been demonstrated to lower intraocular pressure in preclinical models of glaucoma, though a subsequent clinical trial failed to produce similar results in patients with ocular hypertension or open-angle glaucoma [59,60,61]. The gene discussed is SGCB; the disease is glaucoma.